The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.
Dynacure, the France-based muscular disease treatment developer spun out of Institute of Genetic and Molecular and Cellular Biology (IGBMC), has set the range for an initial public offering that could raise up to $107m.
The company plans to offer 6.3 million American depository shares (ADSs), each representing one ordinary share, at a price range of $15 to $17 on the Nasdaq Global Market. The upper end of the range would imply a market valuation of approximately $334m.
Founded in 2016, Dynacure is developing drug treatments for patients with neuromuscular diseases such as myotubular and centronuclear myopathies.
The company will use about $75m to $85m of the IPO proceeds to complete a phase 1/2 trial for its lead product candidate, DYN101, a proposed treatment for centronuclear myopathy.
It also intends to initiate a phase 1/2 trial of DYN101 for children in Europe and begin preparations for future…
